Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03700684 · ClinicalTrials.gov registry record · NA
Voice Treatment for Parkinson's Disease
A NA study of Idiopathic Parkinson Disease, sponsored by University of Massachusetts, Amherst.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT03700684: Completed NA study of Idiopathic Parkinson Disease, sponsored by University of Massachusetts, Amherst.
NCT03700684 is a NA study of Idiopathic Parkinson Disease that has completed, run by University of Massachusetts, Amherst. The registered enrollment target is 36 participants, below the 69-participant average among 4 other Idiopathic Parkinson Disease trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03700684, a NA study of Idiopathic Parkinson Disease, has completed, sponsored by University of Massachusetts, Amherst.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study addresses several issues related to the clinical management of speech and voice disorders associated with Parkinson's disease. Two behavioral treatment programs, Lee Silverman Voice Treatment and SpeechVive, are assessed in their ability to improve communication in persons with Parkinson's disease.
Primary Outcome
Vocal intensity (dB SPL) will be measured during a reading task and a monologue task. The vocal intensity data reported will be collapsed across the reading and monologue task. Recorded speech samples are captured using a head-mounted microphone. The speech signals are analyzed for vocal intensity using Praat. The pre- to post-treatment change in vocal intensity is reported in decibels. A positive value indicates an increase in vocal intensity post-treatment. A negative value indicates a decreas
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Lee Silverman Voice Treatment
- DEVICE SpeechVive
Study Locations (2)
Indiana
- Purdue University - West Lafayette
Massachusetts
- University of Massachusetts Amherst - Amherst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2022-11-30 |
| Phase | NA |
What the finished NCT03700684 record still lists
NCT03700684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 69-participant average among 4 other Idiopathic Parkinson Disease trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Idiopathic Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Control is the first listed.
NCT03700684 reports a single indexed study location in Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03700684 about?
NCT03700684 is a clinical study titled "Voice Treatment for Parkinson's Disease". This study addresses several issues related to the clinical management of speech and voice disorders associated with Parkinson's disease. Two behavioral treatment programs, Lee Silverman Voice Treatment and SpeechVive, are assessed in their ability to improve communication in persons with Parkinson'...
What is the current status of trial NCT03700684?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2018-09-19. Estimated completion is 2022-11-30.
What conditions does trial NCT03700684 study?
This clinical trial studies the following conditions: Idiopathic Parkinson Disease.
What interventions are being tested in trial NCT03700684?
The interventions under investigation include: Control (BEHAVIORAL), Lee Silverman Voice Treatment (BEHAVIORAL), SpeechVive (DEVICE).
Who is sponsoring clinical trial NCT03700684?
This trial is sponsored by University of Massachusetts, Amherst, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03700684 being conducted?
This trial has 2 study locations across Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
COMPLETED · NA
-
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
RECRUITING · Phase 2
-
FDOPA PET and Nutritional Support in Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate in Patients With Parkinsonian Type Disorders
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI